Phases of drug approval
Also known as: clinical trial phases, drug development phases
The phases of drug approval are the sequential clinical trials — Phase I through Phase IV — a candidate drug must pass before and after FDA approval. Each phase enrolls more participants and answers a different question, moving from safety to efficacy to long-term surveillance.
Before any human testing, a sponsor completes preclinical work in cell and animal models and files an Investigational New Drug application with the FDA. Clearance of the IND opens the clinical program.
Phase I enrolls a small group, typically 20 to 100 healthy volunteers, and asks: is it safe? Investigators establish pharmacokinetics, pharmacodynamics, tolerable dose range, and toxicity. Cytotoxic oncology agents are an exception and are tested in patients rather than healthy volunteers. Phase II enrolls a few hundred patients who have the target disease and asks: does it work? This phase establishes preliminary efficacy and optimal dosing while continuing to monitor adverse effects. Phase III enrolls hundreds to thousands of patients in randomized controlled trials and asks: is it better than what we already have? It compares the drug against placebo or standard therapy, generates the statistical evidence for approval, and detects less common adverse effects.
Successful Phase III results support a New Drug Application. If the FDA approves it, the drug enters the market and Phase IV begins: postmarketing surveillance in the general population. Phase IV detects rare adverse events that trials were too small to reveal and monitors long-term safety; findings here can trigger a boxed warning or a market withdrawal.
A useful mnemonic for the questions each phase answers is safety, efficacy, comparison, surveillance. Note also that trial size and duration increase across phases while the population shifts from healthy volunteers to the patients who will actually receive the drug.
USMLE Step 1 tests this in biostatistics and epidemiology. Questions typically describe a trial's size, population, and objective and ask you to name the phase, so anchor on who is enrolled and what question is being asked rather than on memorized participant counts.
Key takeaways
- Preclinical testing and an approved IND application precede any human trials.
- Phase I tests safety, pharmacokinetics, and dosing in a small group of usually healthy volunteers.
- Phase II tests efficacy and optimal dose in a few hundred patients with the disease.
- Phase III is the large randomized controlled comparison against placebo or standard therapy that supports the New Drug Application.
- Phase IV is postmarketing surveillance that detects rare or long-term adverse effects after approval.